Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             59 results found
no title author magazine year volume issue page(s) type
1 Androgen deprivation therapy and cognitive impairment? Bagcchi, Sanjeet
 2015
 16 7 p. e314-
1 p.
 article
2 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Fizazi, Karim
 2015
 16 7 p. 787-794
8 p.
 article
3 Anti-EGFR monoclonal antibodies in lung cancer treatment Schiller, Joan H
 2015
 16 7 p. 738-739
2 p.
 article
4 Artemisia: a divine dart against cancer? Pinato, David J
 2015
 16 7 p. 759-760
2 p.
 article
5 2015 ASCO Annual Meeting Coburn, Cassandra
 2015
 16 7 p. 755-756
2 p.
 article
6 A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study Lin, Xue-Jia
 2015
 16 7 p. 804-815
12 p.
 article
7 A step towards a HER2-positive breast cancer super family von Minckwitz, Gunter
 2015
 16 7 p. 745-746
2 p.
 article
8 Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 Yang, James C-H
 2015
 16 7 p. 830-838
9 p.
 article
9 Combination immunotherapy breakthrough for melanoma Brower, Vicki
 2015
 16 7 p. e318-
1 p.
 article
10 Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial Hurvitz, Sara A
 2015
 16 7 p. 816-829
14 p.
 article
11 Continued value of adjuvant anthracyclines as treatment for early breast cancer Turner, Natalie
 2015
 16 7 p. e362-e369
nvt p.
 article
12 Correction to Lancet Oncol 2015; 16: 738 2015
 16 7 p. e313-
1 p.
 article
13 Correction to Lancet Oncol 2015; 16: 747 2015
 16 7 p. e313-
1 p.
 article
14 Correction to Lancet Oncol 2015; 16: e316 2015
 16 7 p. e313-
1 p.
 article
15 Correction to Lancet Oncol 2015; 16: e227 2015
 16 7 p. e313-
1 p.
 article
16 Could one dose of bivalent HPV vaccine prevent cervical cancer? Brotherton, Julia M L
 2015
 16 7 p. 739-740
2 p.
 article
17 Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology Hoang-Xuan, Khê
 2015
 16 7 p. e322-e332
nvt p.
 article
18 Docetaxel for advanced prostate cancer: how early to start? Armstrong, Andrew J
 2015
 16 7 p. 741-742
2 p.
 article
19 Does ramucirumab deserve a second chance for liver cancer? Forner, Alejandro
 2015
 16 7 p. 751-752
2 p.
 article
20 Early in-patient palliative care consultation saves costs Gunjur, Ashray
 2015
 16 7 p. e321-
1 p.
 article
21 Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials Kreimer, Aimée R
 2015
 16 7 p. 775-786
12 p.
 article
22 EGFR mutations and EGFR tyrosine kinase inhibitors Torri, Valter
 2015
 16 7 p. 746-748
3 p.
 article
23 Feeling Cancer: the social consequences of diagnosis Lucas, Catherine
 2015
 16 7 p. 761-762
2 p.
 article
24 Future of clinical research in the NHS Burki, Talha Khan
 2015
 16 7 p. e315-
1 p.
 article
25 Genomic alterations in lung adenocarcinoma Devarakonda, Siddhartha
 2015
 16 7 p. e342-e351
nvt p.
 article
26 Global cancer cases on the rise Tanday, Sanjay
 2015
 16 7 p. e317-
1 p.
 article
27 GP behaviour and cancer survival? Burki, Talha Khan
 2015
 16 7 p. e317-
1 p.
 article
28 Hepatocellular carcinoma surveillance with miRNAs Forner, Alejandro
 2015
 16 7 p. 743-745
3 p.
 article
29 Interpreting quality-of-life data from the SOFT and TEXT trials Chlebowski, Rowan T
 2015
 16 7 p. 749-751
3 p.
 article
30 Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial Golden, Encouse B
 2015
 16 7 p. 795-803
9 p.
 article
31 Metformin for pancreatic cancer Aung, Kyaw L
 2015
 16 7 p. 748-749
2 p.
 article
32 Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial Kordes, Sil
 2015
 16 7 p. 839-847
9 p.
 article
33 Mismatch repair deficiency predicts benefit of anti-PD-1 therapy Lau, Esther
 2015
 16 7 p. e319-
1 p.
 article
34 Molecular categorisation of gliomas Burki, Talha Khan
 2015
 16 7 p. e320-
1 p.
 article
35 Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial Thatcher, Nick
 2015
 16 7 p. 763-774
12 p.
 article
36 New scale assesses benefits of cancer medicines Bagcchi, Sanjeet
 2015
 16 7 p. e316-
1 p.
 article
37 Nilotinib versus imatinib for GIST Gougis, Paul
 2015
 16 7 p. e311-
1 p.
 article
38 Nilotinib versus imatinib for GIST – Authors' reply Blay, Jean-Yves
 2015
 16 7 p. e311-e312
nvt p.
 article
39 Nivolumab for squamous-cell non-small-cell lung cancer Yaqub, Farhat
 2015
 16 7 p. e319-
1 p.
 article
40 Nowhere girl Bianchi, Andrew
 2015
 16 7 p. 762-
1 p.
 article
41 Palbociclib for hormone receptor-positive breast cancer Harding, Emilia
 2015
 16 7 p. e318-
1 p.
 article
42 Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials Bernhard, Jürg
 2015
 16 7 p. 848-858
11 p.
 article
43 PD-L1 expression by circulating breast cancer cells David, Rachel
 2015
 16 7 p. e321-
1 p.
 article
44 Polypharmacy in patients with advanced cancer and the role of medication discontinuation LeBlanc, Thomas W
 2015
 16 7 p. e333-e341
nvt p.
 article
45 PTSD in parents after childhood cancer Gunjur, Ashray
 2015
 16 7 p. e320-
1 p.
 article
46 Radio-immunotherapy: the focused beam expands Frey, Benjamin
 2015
 16 7 p. 742-743
2 p.
 article
47 Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Zhu, Andrew X
 2015
 16 7 p. 859-870
12 p.
 article
48 Recommendations for screening and early detection of common cancers in India Rajaraman, Preetha
 2015
 16 7 p. e352-e361
nvt p.
 article
49 Targetable mutations found in metastatic prostate cancer Balakrishnan, Vijay Shankar
 2015
 16 7 p. e316-
1 p.
 article
50 TAS-102 for metastatic refractory colorectal cancer Cleghorn, Sean
 2015
 16 7 p. e314-
1 p.
 article
51 Taxane-related nail toxicity Schepisi, Giuseppe
 2015
 16 7 p. e310-e311
nvt p.
 article
52 The C Word Rowe, Hilary
 2015
 16 7 p. 760-761
2 p.
 article
53 The erosion of research integrity: the need for culture change Ellis, Lee M
 2015
 16 7 p. 752-754
3 p.
 article
54 The importance of nurses in cancer care The Lancet Oncology,
 2015
 16 7 p. 737-
1 p.
 article
55 Too many die without dignity Thorley, Jennifer
 2015
 16 7 p. e315-
1 p.
 article
56 Transformation from NSCLC to SCLC: when did it happen? Chen, Baoqing
 2015
 16 7 p. e309-
1 p.
 article
57 Transformation from NSCLC to SCLC: when did it happen? – Authors' reply Engelman, Jeffrey A
 2015
 16 7 p. e309-e310
nvt p.
 article
58 Uneven cost control implementation for US Affordable Care Act Furlow, Bryant
 2015
 16 7 p. 758-
1 p.
 article
59 WHO includes 16 new cancer drugs on list of essential medicines Mayor, Susan
 2015
 16 7 p. 757-
1 p.
 article
                             59 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands